Oppenheimer analyst Jeff Jones maintained a Hold rating on PMV Pharmaceuticals (PMVP – Research Report) today. The company’s shares closed yesterday at $1.67.
Jones covers the Healthcare sector, focusing on stocks such as Fusion Pharmaceuticals, PMV Pharmaceuticals, and Ventyx Biosciences. According to TipRanks, Jones has an average return of 7.6% and a 36.36% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PMV Pharmaceuticals with a $6.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.72 and a one-year low of $1.18. Currently, PMV Pharmaceuticals has an average volume of 545.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PMV Pharmaceuticals (PMVP) Company Description:
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Read More on PMVP:
- PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
- PMV Pharmaceuticals reportsFY23 EPS ($1.44), consensus ($1.52)
- PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
- PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
